8-K: Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results, Highlights Clinical Progress

Adicet Bio announced its Q4 and full year 2024 financial results, highlighting progress in clinical trials for ADI-001 in autoimmune diseases and ADI-270 in solid tumors, along with a cash position of $176.3 million.

Summary

• Adicet Bio reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is advancing its Phase 1 clinical trial of ADI-001 in autoimmune diseases and expects to report preliminary clinical data from the lupus nephritis (LN) patient cohort in the first half of 2025.
• Additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts are anticipated in the second half of 2025.
• Patient enrollment for ADI-001 Phase 1 clinical trials in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), and stiff person syndrome (SPS) is expected to begin in the second quarter of 2025, with anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) patient enrollment expected in the second half of 2025.
• The company is advancing patient enrollment in the ADI-270 Phase 1 clinical trial in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) and plans to report preliminary data in the first half of 2025.
• Adicet Bio had $176.3 million in cash, cash equivalents, and short-term investments as of December 31, 2024.
• R&D expenses for the three months ended December 31, 2024, were $23.3 million, compared to $24.8 million for the same period in 2023.
• G&A expenses for the three months ended December 31, 2024, were $7.5 million, compared to $6.8 million for the same period in 2023.
• Net loss for the three months ended December 31, 2024, was $28.7 million, or $0.32 per share, compared to a net loss of $29.5 million, or $0.69 per share, for the same period in 2023.
• R&D expenses for the year ended December 31, 2024, were $99.3 million, compared to $106.0 million for the year ended December 31, 2023.
• G&A expenses for the year ended December 31, 2024, were $28.3 million, compared to $26.5 million for the year ended December 31, 2023.
• Net loss for the year ended December 31, 2024, was $117.1 million, or $1.33 per share, compared to a net loss of $142.7 million, or $3.31 per share, for the year ended December 31, 2023.
• The company expects its current cash, cash equivalents, and short-term investments will be sufficient to fund operating expenses into the second half of 2026.

Sentiment

Score: 7

Explanation: The announcement is generally positive, highlighting clinical progress, a strong cash position, and FDA Fast Track Designation. While the company reported a net loss, it was lower than the previous year, indicating improvement. The sentiment is cautiously optimistic.

Positives

• Adicet Bio has a strong cash position of $176.3 million, expected to fund operations into the second half of 2026.
• The company received Fast Track Designation for ADI-001 from the FDA, which could expedite the development and review process.
• Adicet is advancing multiple clinical trials for ADI-001 and ADI-270, with preliminary data expected in the near term.
• The appointment of Julie Maltzman as Chief Medical Officer brings significant clinical development and regulatory expertise to the company.

Negatives

• The company reported a net loss of $117.1 million for the year ended December 31, 2024, although this is an improvement compared to the $142.7 million loss in 2023.
• The company is dependent on successful clinical trial outcomes and regulatory approvals, which are inherently uncertain.

Risks

• Clinical studies may fail to demonstrate adequate safety and efficacy of Adicet's product candidates.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable.
• Adicet's ability to meet production and product release expectations is subject to various risks.
• Global economic conditions and public health emergencies could disrupt Adicet's business and financial results.

Future Outlook

Adicet Bio expects its current cash, cash equivalents, and short-term investments will be sufficient to fund its operating expenses into the second half of 2026. The company plans to continue advancing its gamma delta 1 CAR T cell therapy programs, achieving key milestones, and reporting preliminary data in autoimmune and oncology indications.

Management Comments

• In 2025 we plan to continue advancing our gamma delta 1 CAR T cell therapy programs, achieving key milestones and reporting preliminary data in autoimmune and oncology indications, said Chen Schor, President and Chief Executive Officer of Adicet Bio.
• The recent FDA Fast Track Designation for ADI-001 in refractory SLE with extrarenal involvement and in SSc highlights the significant unmet need for innovative, off-the-shelf therapies to treat autoimmune diseases.
• With a strong clinical foundation and growing momentum, Adicet is well-positioned to transform treatment paradigms for patients battling autoimmune diseases and solid tumors.

Industry Context

Adicet Bio is focused on developing allogeneic gamma delta T cell therapies, a novel approach in the fields of autoimmune disease and cancer treatment. The Fast Track Designation for ADI-001 underscores the unmet need for new therapies in these areas. The company's progress in clinical trials and its strong cash position position it to be a player in the competitive biotechnology landscape.

Comparison to Industry Standards

• Adicet Bio's focus on allogeneic gamma delta T cell therapies distinguishes it from companies primarily developing alpha-beta T cell therapies, such as Allogene Therapeutics and Atara Biotherapeutics.
• The $176.3 million cash position provides a runway into the second half of 2026, which is comparable to other clinical-stage biotech companies of similar size and development stage.
• The company's R&D spending is in line with other companies developing novel cell therapies, reflecting the high costs associated with clinical trials and manufacturing development.
• The Fast Track designation for ADI-001 is a positive signal, similar to other companies receiving such designations for promising therapies in areas of unmet need.

Management Changes

Stakeholder Impact

• Shareholders: The announcement provides updates on the company's financial performance and clinical progress, which could influence investor sentiment.
• Employees: The company's strong cash position and clinical advancements could boost employee morale and job security.
• Patients: The progress in clinical trials offers hope for new treatment options for autoimmune diseases and cancer.
• Creditors: The company's financial stability reduces the risk of default on debt obligations.

Next Steps

• Report preliminary clinical data from the lupus nephritis (LN) patient cohort in 1H25.
• Report additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts in 2H25.
• Initiate ADI-001 Phase 1 clinical trial patient enrollment in SLE, SSc, IIM and SPS in 2Q25.
• Initiate AAV patient enrollment in 2H25.
• Report preliminary data from ADI-270 Phase 1 clinical trial in patients with metastatic/advanced ccRCC in 1H25.
• Present ADI-270 data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting in March 2025.

Key Dates